Patents by Inventor Ramon Brugada

Ramon Brugada has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Mutations in ion channel proteins associated with sudden cardiac death
    Patent number: 7745213
    Abstract: Previously unknown mutations of the KCNH2, SCN5A and KCNQ1 genes are disclosed which are involved in ion channel disruptions associated with short QT syndrome, long QT syndrome, Brugada syndrome and progressive conduction disease. These mutations are utilized to diagnose and screen for short QT syndrome, long QT syndrome, Brugada syndrome and progressive conduction disease, thus providing modalities for diagnosing sudden cardiac death and/or predicting susceptibility to sudden cardiac death. Nucleic acid probes are provided which selectively hybridize to the mutant nucleic acids described herein. Antibodies are provided which selectively bind to the mutant proteins described herein. The mutations described herein are also utilized to screen for compounds useful in treating the symptoms manifest by such mutations.
    Type: Grant
    Filed: March 30, 2009
    Date of Patent: June 29, 2010
    Assignee: Masonic Medical Research Laboratory
    Inventors: Charles Antzelevitch, Ramon Brugada, Kui Hong
  • MUTATIONS IN ION CHANNEL PROTEINS ASSOCIATED WITH SUDDEN CARDIAC DEATH
    Publication number: 20090317905
    Abstract: Previously unknown mutations of the KCNH2, SCN5A and KCNQ1 genes are disclosed which are involved in ion channel disruptions associated with short QT syndrome, long QT syndrome, Brugada syndrome and progressive conduction disease. These mutations are utilized to diagnose and screen for short QT syndrome, long QT syndrome, Brugada syndrome and progressive conduction disease, thus providing modalities for diagnosing sudden cardiac death and/or predicting susceptibility to sudden cardiac death. Nucleic acid probes are provided which selectively hybridize to the mutant nucleic acids described herein. Antibodies are provided which selectively bind to the mutant proteins described herein. The mutations described herein are also utilized to screen for compounds useful in treating the symptoms manifest by such mutations.
    Type: Application
    Filed: March 30, 2009
    Publication date: December 24, 2009
    Applicant: MASONIC MEDICAL RESEARCH LABORATORY
    Inventors: Charles Antzelevitch, Ramon Brugada, Kui Hong
  • Mutations in ion channel proteins associated with sudden cardiac death
    Patent number: 7537928
    Abstract: Previously unknown mutations of the KCNH2, SCN5A and KCNQ1 genes are disclosed which are involved in ion channel disruptions associated with short QT syndrome, long QT syndrome, Brugada syndrome and progressive conduction disease. These mutations are utilized to diagnose and screen for short QT syndrome, long QT syndrome, Brugada syndrome and progressive conduction disease, thus providing modalities for diagnosing sudden cardiac death and/or predicting susceptibility to sudden cardiac death. Nucleic acid probes are provided which selectively hybridize to the mutant nucleic acids described herein. Antibodies are provided which selectively bind to the mutant proteins described herein. The mutations described herein are also utilized to screen for compounds useful in treating the symptoms manifest by such mutations.
    Type: Grant
    Filed: August 23, 2004
    Date of Patent: May 26, 2009
    Assignee: Masonic Medical Research Laboratory
    Inventors: Charles Antzelevitch, Ramon Brugada, Kui Hong
  • Mutations in ion channel proteins associated with sudden cardiac death
    Publication number: 20050130190
    Abstract: Previously unknown mutations of the KCNH2, SCN5A and KCNQ1 genes are disclosed which are involved in ion channel disruptions associated with short QT syndrome, long QT syndrome, Brugada syndrome and progressive conduction disease. These mutations are utilized to diagnose and screen for short QT syndrome, long QT syndrome, Brugada syndrome and progressive conduction disease, thus providing modalities for diagnosing sudden cardiac death and/or predicting susceptibility to sudden cardiac death. Nucleic acid probes are provided which selectively hybridize to the mutant nucleic acids described herein. Antibodies are provided which selectively bind to the mutant proteins described herein. The mutations described herein are also utilized to screen for compounds useful in treating the symptoms manifest by such mutations.
    Type: Application
    Filed: August 23, 2004
    Publication date: June 16, 2005
    Inventors: Charles Antzelevitch, Ramon Brugada, Kui Hong